Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia

Stopped Novartis is no longer pursuing this study because of planned investigation of novel CAR-T therapies in this patient population.

Conditions

• Acute Lymphoblastic Leukemia

Interventions

• BIOLOGICAL: Tisagenlecleucel
• DRUG: Blinatumomab
• DRUG: Inotuzumab

Sponsor

Novartis Pharmaceuticals